ABBV-303

N/A

Report date: 2025/10/28 20:00:08

Base Information

Drug NameABBV-303

Drug Alias NameABBV-303DF-4101

ClassificationBiologics

Mechanisms of ActionNKG2D ligands modulatorsHepatocyte growth factor receptor modulatorsLow affinity immunoglobulin gamma Fc region receptor III agonists

TargetsNKG2D ligandsHepatocyte growth factor receptorLow affinity immunoglobulin gamma Fc region receptor III

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesIsraelJapan

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesDragonfly Therapeutics Llc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbvie Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A